FDA approves Skyline Therapeutics’ IND for macular degeneration trial
Gene TherapyINDClinical StudyAcquisition
Preview
Source: Pharmaceutical Technology
Robert Barrie
Preview
Source: Pharmaceutical Technology
nAMD, which leads to severe visual impairment, is estimated to affect over 200 million people worldwide. Image credit: Shutterstock/air009.
Preview
Source: Pharmaceutical Technology
Chinese gene therapy company Skyline will initiate a global trial investigating a gene therapy to treat neovascular age-related macular degeneration (nAMD), after receiving clearance from the US Food and Drug Administration (FDA).
The FDA granted the company’s investigational new drug (IND) application for a Phase I/IIa trial of SKG0106 – a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ranibizumab Biosimilar in Macular Edema GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ranibizumab Sr in Macular Edema GlobalData
View allCompanies IntelligenceNovartis AGGyroscope Therapeutics LimitedCytivaSky LineView all
Skyline has not disclosed when it expects to initiate the trial.
Skyline Therapeutics’ candidate encompasses a new AAV capsid and unique transgene genome encoding an anti-VEGF protein. Vascular endothelial growth factor (VEGF) is a protein that promotes the growth of new blood vessels and also makes vessels more permeable or leaky. Patients with macular degeneration secrete too much of this protein.
The company’s anti-angiogenic treatment is able to suppress neovascular lesions at a low dose with durable effects from a single injection. The prevention of neovascularisation provides relief of vascular leakage and retinal oedema.
According to Skyline Therapeutics, preclinical studies with the candidate have demonstrated the efficacy of intraocular neovascularisation inhibition, a favourable safety profile, and long-lasting effects from a single administration.
The clinical trial landscape is saturated with medicines for nAMD. Gene therapy in the field is emerging. In 2021, Novartis bought Gyroscope Therapeutics, and by virtue of its AMD gene therapy candidate, in a $1.5bn deal.
Patients with nAMD, otherwise known as wet AMDAMD, have severe visual impairment that becomes permanent. The condition is estimated to affect more than 200 million people worldwide.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.